ErbB-2受体与肿瘤多药耐药的研究进展
肿瘤;ErbB-2;多药耐药,张红,高青,通讯作者:,ProgressinresearchintotherelationshipofErbB-2andmultidrugresistance,HongZhang,QingGao,Correspond
 |
| 第1页 |
参见附件(836KB，4页)。
张红, 高青, 重庆医科大学附属第一医院消化内科 重庆市 400016
通讯作者: 张红, 400016, 重庆医科大学255号信箱, 重庆医科大学附属第一医院消化内科. zhanghongdina@sina.com
收稿日期: 2007-03-06 接受日期: 2007-05-16
Progress in research into the relationship of ErbB-2 and multidrug resistance
Hong Zhang, Qing Gao
Hong Zhang, Qing Gao,Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Correspondence to:Hong Zhang, Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. zhanghongdina@sina.com
Received:2007-03-06 Accepted:2007-05-16
Abstract
One of the most common yet difficult to resolve problems in clinical tumor chemotherapy is multidrug resistance (MDR). It is also the major factor leading to tumor recurrence, even to metastasis. Hence, investigations into multidrug resistance of tumors have recently become very common. New therapeutic targets have been discovered based on molecular research into tumor lesions as ErbB-2. These should provide possibilities for reversing tumor MDR by developing new types of antitumor drugs that have higher performance and are less harmful than existing treatments.
Key Words: Tumor; ErbB-2; Multidrug resistance
Zhang H, Gao Q. Progress in research into the relation-ship of ErbB-2 and multidrug resistance. Shijie Huaren Xiaohua Zazhi 2007;15(18):2042-2045
摘要
肿瘤细胞多药耐药是临床肿瘤化疗失败最常见和最难克服的问题之一, 亦是复发、转移的主要原因. 因此肿瘤耐药逆转成为当今肿瘤研究中的热点之一. 近年来, 基于对肿瘤病灶部位的分子水平的研究, 发现了许多新的治疗靶点, 如ErbB-2, 为开发新型的高效低毒的新药从而逆转肿瘤多药耐药提供了可能.
关键词: 肿瘤; ErbB-2; 多药耐药
张红, 高青. ErbB-2受体与肿瘤多药耐药的研究进展. 世界华人消化杂志 2007;15(18):2042-2045
0 引言
目前, 化疗是恶性肿瘤治疗中除手术、放疗以外最重要的手段, 肿瘤对化疗药物产生耐药性是目前肿瘤治疗失败的一个重要原因, 已经发现很多机制参与肿瘤耐药性的产生. ErbB受体家族成员在多种人类恶性肿瘤中有表达或高表达, 已知在60%的肿瘤中存在1个或多个ErbB受体过度表达, 尤其在实体瘤中, 如肺癌、乳腺癌、胃癌、前列腺癌、卵巢癌、头颈部肿瘤等, 人们逐渐发现EerB-2参与耐药的形成. 现就EerB-2与肿瘤多药耐药的研究作一综述 ......
您现在查看是摘要介绍页，详见PDF附件(836KB，4页)。